GDF15 and heart failure: According to the 2022 meta-analysis performed using data pooled from eight trials including 53,486 patients, GDF-15 consistently added prognostic information for cardiovascular death and hospitalization for heart failure across the spectrum of atherosclerotic cardiovascular disease [120].